U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07669779) titled 'A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer' on June 21.
Brief Summary: This is a phase II clinical study evaluating the safety, tolerability, pharmacokinetics and antitumor efficacy of AK146D1 in combination with AK112 or other anticancer therapies in patients with advanced Non-Small Cell Lung Cancer.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Advanced Non Small Cell Lung Cancer (NSCLC)
Intervention:
DRUG: AK146D1 for injection
AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate.
DRUG: AK112 Injection
AK112 is a PD-1/VEGF bi...